Ann: Opthea Reports Half Year Results and Business Updates, page-16

I'd thought the business had noted that through their funding arrangement that they would have the cash to support closure of phase 3. I've always been of the opinion that should they be successful with FDA approval, then they'll most definitely pass the hat around to fund commercialisation. I wouldn't be adding anymore to my holdings for any CR pre FDA outcome especially when we're already sitting at 1.2b shares outstanding. Post FDA outcome - well that's a different beast altogether.